152 related articles for article (PubMed ID: 28826086)
1. An update on small molecules targeting CXCR4 as starting points for the development of anti-cancer therapeutics.
Grande F; Giancotti G; Ioele G; Occhiuzzi MA; Garofalo A
Eur J Med Chem; 2017 Oct; 139():519-530. PubMed ID: 28826086
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel 2-(1H-indol-1-yl)-benzohydrazides CXCR4 ligands impairing breast cancer growth and motility.
Grande F; Barone I; Aiello F; Brancale A; Cancellieri M; Badolato M; Chemi F; Giordano C; Vircillo V; Bonofiglio D; Garofalo A; Andò S; Catalano S
Future Med Chem; 2016; 8(2):93-106. PubMed ID: 26807787
[TBL] [Abstract][Full Text] [Related]
3. Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.
Choi WT; Yang Y; Xu Y; An J
Curr Top Med Chem; 2014; 14(13):1574-89. PubMed ID: 25159167
[TBL] [Abstract][Full Text] [Related]
4. The chemokine receptor CXCR4 as a therapeutic target for several diseases.
Tamamura H; Tsutsumi H; Fujii N
Mini Rev Med Chem; 2006 Sep; 6(9):989-95. PubMed ID: 17017998
[TBL] [Abstract][Full Text] [Related]
5. Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities.
Zhang H; Kang D; Huang B; Liu N; Zhao F; Zhan P; Liu X
Eur J Med Chem; 2016 May; 114():65-78. PubMed ID: 26974376
[TBL] [Abstract][Full Text] [Related]
6. Small molecule inhibitors of CXCR4.
Debnath B; Xu S; Grande F; Garofalo A; Neamati N
Theranostics; 2013; 3(1):47-75. PubMed ID: 23382786
[TBL] [Abstract][Full Text] [Related]
7. Targeting the production of oncogenic microRNAs with multimodal synthetic small molecules.
Vo DD; Staedel C; Zehnacker L; Benhida R; Darfeuille F; Duca M
ACS Chem Biol; 2014 Mar; 9(3):711-21. PubMed ID: 24359019
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents.
Tsutsumi H; Tanaka T; Ohashi N; Masuno H; Tamamura H; Hiramatsu K; Araki T; Ueda S; Oishi S; Fujii N
Biopolymers; 2007; 88(2):279-89. PubMed ID: 17167792
[TBL] [Abstract][Full Text] [Related]
9. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
Kijima T; Maulik G; Ma PC; Tibaldi EV; Turner RE; Rollins B; Sattler M; Johnson BE; Salgia R
Cancer Res; 2002 Nov; 62(21):6304-11. PubMed ID: 12414661
[TBL] [Abstract][Full Text] [Related]
10. CXCR4 receptor as a promising target for oncolytic drugs.
Lavrovsky Y; Ivanenkov YA; Balakin KV; Medvedeva DA; Ivachtchenko AV
Mini Rev Med Chem; 2008 Oct; 8(11):1075-87. PubMed ID: 18855724
[TBL] [Abstract][Full Text] [Related]
11. Progress toward rationally designed small-molecule peptide and peptidomimetic CXCR4 antagonists.
Våbenø J; Haug BE; Rosenkilde MM
Future Med Chem; 2015; 7(10):1261-83. PubMed ID: 26144264
[TBL] [Abstract][Full Text] [Related]
12. Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure.
Cox BD; Prosser AR; Katzman BM; Alcaraz AA; Liotta DC; Wilson LJ; Snyder JP
Chembiochem; 2014 Jul; 15(11):1614-20. PubMed ID: 24990206
[TBL] [Abstract][Full Text] [Related]
13. Discovery and computer aided potency optimization of a novel class of small molecule CXCR4 antagonists.
Vinader V; Ahmet DS; Ahmed MS; Patterson LH; Afarinkia K
PLoS One; 2013; 8(10):e78744. PubMed ID: 24205302
[TBL] [Abstract][Full Text] [Related]
14. Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics.
Maschinot CA; Pace JR; Hadden MK
Curr Med Chem; 2015; 22(35):4033-57. PubMed ID: 26310919
[TBL] [Abstract][Full Text] [Related]
15. The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer.
Otsuka S; Bebb G
J Thorac Oncol; 2008 Dec; 3(12):1379-83. PubMed ID: 19057260
[TBL] [Abstract][Full Text] [Related]
16. Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.
Das D; Maeda K; Hayashi Y; Gavande N; Desai DV; Chang SB; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2015 Apr; 59(4):1895-904. PubMed ID: 25583709
[TBL] [Abstract][Full Text] [Related]
17. Discovery of small molecule CXCR4 antagonists.
Zhan W; Liang Z; Zhu A; Kurtkaya S; Shim H; Snyder JP; Liotta DC
J Med Chem; 2007 Nov; 50(23):5655-64. PubMed ID: 17958344
[TBL] [Abstract][Full Text] [Related]
18. Salvianolic acid B inhibits SDF-1α-stimulated cell proliferation and migration of vascular smooth muscle cells by suppressing CXCR4 receptor.
Pan CH; Chen CW; Sheu MJ; Wu CH
Vascul Pharmacol; 2012; 56(1-2):98-105. PubMed ID: 22166584
[TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists.
Mishra RK; Shum AK; Platanias LC; Miller RJ; Schiltz GE
Sci Rep; 2016 Jul; 6():30155. PubMed ID: 27456816
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel potent MDM2/p53 small-molecule inhibitors.
Ivanenkov YA; Vasilevski SV; Beloglazkina EK; Kukushkin ME; Machulkin AE; Veselov MS; Chufarova NV; Chernyaginab ES; Vanzcool AS; Zyk NV; Skvortsov DA; Khutornenko AA; Rusanov AL; Tonevitsky AG; Dontsova OA; Majouga AG
Bioorg Med Chem Lett; 2015 Jan; 25(2):404-9. PubMed ID: 25479770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
